

# **Cytotoxicity assessment of exfoliated MoS<sub>2</sub> using primary human mast cells and the progenitor cell-derived mast cell line LAD2<sup>†</sup>**

Hazel Lin,<sup>1</sup> Antonio Esau del Rio Castillo,<sup>2</sup> Viviana Jehová González,<sup>3</sup> Francesco Bonaccorso,<sup>2</sup> Ester Vázquez,<sup>3</sup> Bengt Fadeel,<sup>4</sup> Alberto Bianco<sup>1,\*</sup>


<sup>1</sup>CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572, University of Strasbourg, ISIS, 67000 Strasbourg, France

<sup>2</sup>BeDimensional, Lungo Torrente Secca 30r, Genoa, Italy


<sup>3</sup>Biograph Solutions, Regional Institute of Applied Scientific Research (IRICA), Department of Organic Chemistry, Faculty of Science and Chemistry Technologies, University of Castilla-La Mancha, Ciudad Real 13071, Spain

<sup>4</sup>Nanosafety & Nanomedicine Laboratory, Institute of Environmental Medicine, Karolinska Institutet, 177 77 Stockholm, Sweden


## **ELECTRONIC SUPPLEMENTARY INFORMATION**




**Figure S1. Characterization of primary mast cells.** Optical microscopy images of primary mast cells (A) stained with acidic toluidine blue. Flow cytometry characterization of primary mast cells (B) stained with FceRI and CD117.




**Figure S2. Characterization of LAD2 cells.** Optical microscopy images of primary mast cells (A) stained with acidic toluidine blue. Flow cytometry characterization of LAD2 cells (B) stained with FceRI and CD117.



**Figure S3. TEM and AFM analysis of MoS<sub>2</sub>.** (A) TEM image of selected BD-MoS<sub>2</sub> flakes; (B) TEM image of selected BS-MoS<sub>2</sub> flakes; (C) AFM image of selected BD-MoS<sub>2</sub> flakes; (D) AFM image of selected BD-MoS<sub>2</sub> flakes.



**Figure S4. ROS production in primary mast cells and LAD2 cells.** ROS production of (A) primary mast cells (B) LAD2 cells treated with 5, 50  $\mu\text{g mL}^{-1}$  BD- or BS-MoS<sub>2</sub> for 1h and stained with CM-H2DCFDA. All experiments were conducted thrice in triplicate and shown as mean  $\pm$  SD. \*P<0.05; \*\*P<0.01, \*\*\*P<0.001 by one-way ANOVA with Bonferroni post-tests.



**Figure S5. SEM of unexposed and exposed LAD2 cells.** (A) Untreated LAD2 cells. LAD2 cells treated with 50  $\mu\text{g mL}^{-1}$  (B) BD-MoS<sub>2</sub> or (C) BS-MoS<sub>2</sub> for 1h.